Biogen’s Q3 Aduhelm Sales Even Worse Than Expected
Executives Emphasize Low Expectations Through Year-End
Analysts expected at least $12m in third quarter sales, but the Alzheimer’s therapy brought in just $300,000. The company says educating doctors and procuring a coverage determination from CMS – not lower pricing – are key to growth.
